(Q34107663)

31 July 2017

1 reference

title

Dose-intensive approaches to ovarian cancer (English)

1 reference

31 July 2017

1 reference

N Lambrou

1

1 reference

PubMed ID

11122798

31 July 2017

E L Trimble

series ordinal

2

1 reference

31 July 2017

1 September 1999

1 reference

31 July 2017

Current Oncology Reports

1 reference

31 July 2017

1

1 reference

31 July 2017

1

1 reference

31 July 2017

54-58

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-999-0010-x

31 July 2017

0 references

cites work

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-999-0010-X

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

21 January 2018

1 reference

12 December 2020

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer

1 reference

12 December 2020

A phase I study of paclitaxel, doxorubicin, and cisplatin in patients with previously untreated epithelial ovarian cancer

1 reference

12 December 2020

High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients

1 reference

12 December 2020

Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

12 December 2020

How many more nails to seal the coffin of dose intensity?

1 reference

12 December 2020

A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

12 December 2020

First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?

1 reference

12 December 2020

Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma.

1 reference

12 December 2020

Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group

1 reference

12 December 2020

Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study

1 reference

12 December 2020

A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer

1 reference

12 December 2020

Taxane/platinum/anthracycline combination therapy in advanced epithelial ovarian cancer.

1 reference

12 December 2020

Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer

1 reference

12 December 2020

A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment

1 reference

12 December 2020

Advanced epithelial ovarian cancer: 1998 consensus statements

1 reference

12 December 2020

Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer

1 reference

12 December 2020

Dose-intensity in ovarian carcinoma: hold, enough?

1 reference

12 December 2020

10.1007/S11912-999-0010-X

Identifiers

DOI

1 reference

PubMed ID

11122798

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

11122798